Abstract
MicroRNAs are small non-coding RNAs that regulate gene expression at the posttranscriptional level by either inhibiting mRNA translation or inducing mRNA degradation. These regulatory mechanisms occur in a sequence-specific manner through the direct binding of the microRNA to complementary reverse sequences in the 3 UTR of target mRNAs. The sequence-specific nature of microRNAs allows for the regulation of numerous target mRNAs, which often are related genes, resulting in the robust regulation of entire pathways. Previous studies have identified expression signatures of microRNAs during various pathological settings, including those of cardiovascular disease. As evident through gain- and loss-of-function studies in mice, it is apparent microRNAs play specific and essential roles during cardiac hypertrophy, fibrosis, angiogenesis, apoptosis, and contractility. The powerful effects of altering microRNA levels genetically have resulted in the rapid progression of oligo-based regulation of microRNAs as a new class of cardiovascular therapeutics. Here we summarize the current oligo-based technologies in use to regulate microRNA levels in vivo and how these technologies have been applied to multiple microRNAs during cardiovascular disease.
Keywords: microRNA, miRNA, heart failure, cardiovascular disease, anti-miR, therapeutics, oligonucleotides, gene regulation
Current Drug Targets
Title: microRNA Regulation as a Therapeutic Strategy for Cardiovascular Disease
Volume: 11 Issue: 8
Author(s): Rusty L. Montgomery and Eva van Rooij
Affiliation:
Keywords: microRNA, miRNA, heart failure, cardiovascular disease, anti-miR, therapeutics, oligonucleotides, gene regulation
Abstract: MicroRNAs are small non-coding RNAs that regulate gene expression at the posttranscriptional level by either inhibiting mRNA translation or inducing mRNA degradation. These regulatory mechanisms occur in a sequence-specific manner through the direct binding of the microRNA to complementary reverse sequences in the 3 UTR of target mRNAs. The sequence-specific nature of microRNAs allows for the regulation of numerous target mRNAs, which often are related genes, resulting in the robust regulation of entire pathways. Previous studies have identified expression signatures of microRNAs during various pathological settings, including those of cardiovascular disease. As evident through gain- and loss-of-function studies in mice, it is apparent microRNAs play specific and essential roles during cardiac hypertrophy, fibrosis, angiogenesis, apoptosis, and contractility. The powerful effects of altering microRNA levels genetically have resulted in the rapid progression of oligo-based regulation of microRNAs as a new class of cardiovascular therapeutics. Here we summarize the current oligo-based technologies in use to regulate microRNA levels in vivo and how these technologies have been applied to multiple microRNAs during cardiovascular disease.
Export Options
About this article
Cite this article as:
L. Montgomery Rusty and van Rooij Eva, microRNA Regulation as a Therapeutic Strategy for Cardiovascular Disease, Current Drug Targets 2010; 11 (8) . https://dx.doi.org/10.2174/138945010791591368
DOI https://dx.doi.org/10.2174/138945010791591368 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Pathology Induced by Highly Active Antiretroviral Therapy Against Human Immunodeficiency Virus: an Update
Current Medicinal Chemistry New Genetic Polymorphisms as an Epidemiological Factor of Arterial Hypertension in Patients with Hyposodical Diet
Current Hypertension Reviews Novel Carriers for Coenzyme Q10 Delivery
Current Drug Delivery Mitochondrial Dysfunction and Endoplasmic Reticulum Stress in Diabetes
Current Pharmaceutical Design Thrombotic Thrombocytopenic Purpura and Anti-Thrombotic Therapy Targeted to Von Willebrand Factor
Current Vascular Pharmacology Heart Failure Models: Traditional and Novel Therapy
Current Vascular Pharmacology Hutchinson-Gilford Progeria Syndrome: An Overview of the Molecular Mechanism, Pathophysiology and Therapeutic Approach
Current Gene Therapy Peptidomimetic Inhibitors of Cathepsin K
Current Topics in Medicinal Chemistry Natural and Synthetic Naphthoquinones Active Against Trypanosoma Cruzi: An Initial Step Towards New Drugs for Chagas Disease
Current Medicinal Chemistry Novel Agents Targeting Nitric Oxide
Current Vascular Pharmacology Endothelial Cell Senescence and Inflammaging: MicroRNAs as Biomarkers and Innovative Therapeutic Tools
Current Drug Targets Pharmacological and Non Pharmacological Strategies in the Management of Coronary Artery Disease and Chronic Kidney Disease
Current Cardiology Reviews Stem Cell Therapy in Heart Diseases: A Review of Selected New Perspectives,Practical Considerations and Clinical Applications
Current Cardiology Reviews Dietary Carbohydrates that Modulate the Immune System
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Clinical and Pharmacological Aspects of Immunoprophylaxis for Respiratory Syncytial Virus Infection in High-Risk Infants
Current Drug Metabolism Immunomodulatory Activity of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Advanced Glycation and ROS: A Link between Diabetes and Heart Failure
Current Vascular Pharmacology The Role of Stem Cells in Muscular Dystrophies
Current Gene Therapy Glucocorticoid Analogues: Potential Therapeutic Alternatives for Treating Inflammatory Muscle Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Out-of-Hospital Cardiac Arrest –Optimal Management
Current Cardiology Reviews